CStone Pharmaceuticals
HKEX:2616

Watchlist Manager
CStone Pharmaceuticals Logo
CStone Pharmaceuticals
HKEX:2616
Watchlist
Price: 7.83 HKD 4.26%
Market Cap: 10.7B HKD

Net Margin
CStone Pharmaceuticals

-22.4%
Current
-231%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-22.4%
=
Net Income
-91.2m
/
Revenue
407.2m

Net Margin Across Competitors

CStone Pharmaceuticals
Glance View

Market Cap
10.1B HKD
Industry
Biotechnology

Cstone Pharmaceuticals Co. Ltd. engages in the research and development of highly complex biopharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 264 full-time employees. The company went IPO on 2019-02-26. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The firm conducts its businesses mainly in domestic market.

Intrinsic Value
3.59 HKD
Overvaluation 54%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-22.4%
=
Net Income
-91.2m
/
Revenue
407.2m
What is the Net Margin of CStone Pharmaceuticals?

Based on CStone Pharmaceuticals's most recent financial statements, the company has Net Margin of -22.4%.

Back to Top